MedTrace is scaling fast and expect to continue its growth internationally. With the inauguration of the company’s new U.S. headquarters, MedTrace is shortening the distance to important trial partners, talented new employees, and business opportunities.

“We are thrilled to welcome MedTrace to downtown Minneapolis and are excited to have their bespoke U.S. headquarters at IDS Center,” says Steve Cramer, president & ceo, mpls downtown council. He continues:

“MedTrace and their leadership in the perfusion imaging space is a great fit with the innovative companies who call downtown home. Having businesses like MedTrace show their commitment to our downtown as an integral part of their plans moving forward is another testament to the advantages our city’s core provides businesses and their growth. We look forward to having MedTrace here at IDS Center for years to come,” Steve Cramer says.

As part of the international scaling of MedTrace, Danish co-founder and COO Rune Wiik Kristensen will relocate to Minneapolis and add “U.S. President” to his business card.

“Minneapolis is the place to be for any ambitious international healthtech or medtech company. We have been coming here for years and we have done our due diligence. The talent pool is immense, and Minnesota Nice fits well with Scandinavian culture. My family and I are very excited to start calling MSP our home,” says Rune Wiik Kristensen, COO and U.S. President at MedTrace. He continues:

“On behalf of MedTrace we look forward to growing our business and work even closer with our excellent current partners, to form new alliances across the industry spectrum, and to expand our team with new talent,” he says.

The pharma and device company are perfusion imaging specialists focusing on technology that automatically produces and administers the PET tracer 15O-water to patients at the point of care for absolute quantification of blood flow.

In May, MedTrace announced First Subject Scanned in the company’s RAPID-WATER-FLOW Phase 3 Clinical Trial. The scan took place just two months after MedTrace received FDA approval of the company’s Investigational New Drug (IND) application and the approval to commence the trial.

Upload a file